NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Middle East Conflict Impacts Australia and New Zealand Businesses 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
(4) - EconoTimes)
CAMBRIDGE, Mass., April 30, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on April 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to forty individuals hired by Sarepta in April 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 170,959 shares of Sarepta's common stock. The options have an exercise price of $76.36 per share, which is equal to the closing price of Sarepta's common stock on April 30, 2018. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
